Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 3/2021

01.03.2021 | Small Intestine (D Sachar and AC Stein)

Luminal Gastrointestinal Manifestations of Cystic Fibrosis

verfasst von: Samuel J Burton, Christine Hachem, James M. Abraham

Erschienen in: Current Gastroenterology Reports | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

People with cystic fibrosis (CF) are living longer. General age-related and CF-specific gastrointestinal symptoms are increasingly recognized. In this article, we review the latest data on luminal gastrointestinal manifestations in CF.

Recent Findings

People with CF have increased incidence of gastroesophageal reflux disease symptoms and often prescribed proton-pump inhibitors (PPI). PPI use may increase risk of pulmonary exacerbations. Evidence to support gastric fundoplication to improve pulmonary outcomes is limited. Features of intestinal dysmotility are common. There are distinct differences in the gut microbiome in the CF population which may have clinical implications. CF is a possible hereditary digestive cancer syndrome, particularly in regard to colorectal cancer (CRC) with earlier incidence of CRC and advanced colonic neoplasia. Early screening colonoscopy is warranted in the CF population.

Summary

Gastrointestinal manifestations in CF are prevalent across all digestive organs. More study on the effect of interventions for symptomatic treatment and cancer screening is needed.
Literatur
1.
2.
MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161(4):233–41.PubMedPubMedCentralCrossRef
3.
Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17(2):218–27.PubMedPubMedCentralCrossRef
4.
Cystic Fibrosis Foundation patient registry annual data report. 2018.
5.
Balfour-Lynn IM, King JA. CFTR modulator therapies - effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev. 2020.
6.
Pauwels A, Blondeau K, Dupont LJ, Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol. 2012;107(9):1346–53.PubMedCrossRef
7.
Blondeau K, Dupont LJ, Mertens V, Verleden G, Malfroot A, Vandenplas Y, et al. Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. Gut. 2008;57(8):1049–55.PubMedCrossRef
8.
Button BM, Roberts S, Kotsimbos TC, Levvey BJ, Williams TJ, Bailey M, et al. Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant. 2005;24(10):1522–9.PubMedCrossRef
9.
Maqbool A, Pauwels A. Cystic fibrosis and gastroesophageal reflux disease. J Cyst Fibros. 2017;16(Suppl 2):S2–S13.PubMedCrossRef
10.
Kunzelmann K, Schreiber R, Hadorn HB. Bicarbonate in cystic fibrosis. J Cyst Fibros. 2017;16(6):653–62.PubMedCrossRef
11.
Posner S, Mehta K, Parish A, Niedzwiecki D, Gupta RT, Fisher DA, et al. Esophageal function tests are not associated with barium swallow findings in advanced lung disease. Dysphagia. 2020.
12.
Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European epidemiologic registry of cystic fibrosis. Eur Respir J. 2001;18(2):298–305.PubMedCrossRef
13.
van der Doef HP, Arets HG, Froeling SP, Westers P, Houwen RH. Gastric acid inhibition for fat malabsorption or gastroesophageal reflux disease in cystic fibrosis: longitudinal effect on bacterial colonization and pulmonary function. J Pediatr. 2009;155(5):629–33.PubMedCrossRef
14.
McCrory BE, Harper HN, GL MP. Use and incidence of adverse effects of proton pump inhibitors in patients with cystic fibrosis. Pharmacotherapy. 2018.
15.
Ayoub F, Lascano J, Morelli G. Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis. Gastroenterology Res. 2017;10(5):288–93.PubMedPubMedCentralCrossRef
16.
Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med. 2014;14:21.PubMedPubMedCentralCrossRef
17.
Knotts RM, Solfisburg QS, Keating C, DiMango E, Lightdale CJ, Abrams JA. Cystic fibrosis is associated with an increased risk of Barrett's esophagus. J Cyst Fibros. 2019;18(3):425–9.PubMedCrossRef
18.
Hassall E, Israel DM, Davidson AG, Wong LT. Barrett's esophagus in children with cystic fibrosis: not a coincidental association. Am J Gastroenterol. 1993;88(11):1934–8.PubMed
19.•
Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003;95(5):381–7 Initial prospective cohort report of cancer incidence in in the US.PubMedCrossRef
20.•
Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105(2):122–9 Follow-up 20 year report of increased GI cancer incidience in US with increased risk in post lung transplant.PubMedCrossRef
21.
Ng SM, Moore HS. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;8:CD003424.
22.
Sheikh SI, Ryan-Wenger NA, McCoy KS. Outcomes of surgical management of severe GERD in patients with cystic fibrosis. Pediatr Pulmonol. 2013;48(6):556–62.PubMedCrossRef
23.
Zeybel GL, Pearson JP, Krishnan A, Bourke SJ, Doe S, Anderson A, et al. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. J Cyst Fibros. 2017;16(1):124–31.PubMedPubMedCentralCrossRef
24.
Mendez BM, Davis CS, Weber C, Joehl RJ, Fisichella PM. Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis. Am J Surg. 2012;204(5):e21–6.PubMedCrossRef
25.
Jamie Dy F, Freiberger D, Liu E, Boyer D, Visner G, Rosen R. Impact of gastroesophageal reflux and delayed gastric emptying on pediatric lung transplant outcomes. J Heart Lung Transplant. 2017;36(8):854–61.PubMedCrossRef
26.
Cantu E 3rd, Appel JZ 3rd, Hartwig MG, Woreta H, Green C, Messier R, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78(4):1142–51 discussion −51.PubMedCrossRef
27.
Lo WK, Goldberg HJ, Wee J, Fisichella PM, Chan WW. Both pre-transplant and early post-transplant antireflux surgery prevent development of early allograft injury after lung transplantation. J Gastrointest Surg. 2016;20(1):111–8 discussion 8.PubMedCrossRef
28.
Lo WK, Goldberg HJ, Boukedes S, Burakoff R, Chan WW. Proton pump inhibitors independently protect against early allograft injury or chronic rejection after lung transplantation. Dig Dis Sci. 2018;63(2):403–10.PubMedCrossRef
29.
Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest. 1994;93(1):347–54.PubMedPubMedCentralCrossRef
30.
Yeh KM, Johansson O, Le H, Rao K, Markus I, Perera DS, et al. Cystic fibrosis transmembrane conductance regulator modulates enteric cholinergic activities and is abnormally expressed in the enteric ganglia of patients with slow transit constipation. J Gastroenterol. 2019;54(11):994–1006.PubMedCrossRef
31.
Xue R, Gu H, Qiu Y, Guo Y, Korteweg C, Huang J, et al. Expression of cystic fibrosis transmembrane conductance regulator in ganglia of human gastrointestinal tract. Sci Rep. 2016;6:30926.PubMedPubMedCentralCrossRef
32.
Crites KS, Morin G, Orlando V, Patey N, Cantin C, Martel J, et al. CFTR knockdown induces proinflammatory changes in intestinal epithelial cells. J Inflamm (Lond). 2015;12:62.CrossRef
33.
Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the cystic fibrosis intestine. J Cyst Fibros. 2017;16(Suppl 2):S14–23.PubMedCrossRef
34.
Corral JE, Dye CW, Mascarenhas MR, Barkin JS, Salathe M, Moshiree B. Is gastroparesis found more frequently in patients with cystic fibrosis? A systematic review. Scientifica (Cairo). 2016;2016:2918139.
35.
Ng C, Dellschaft NS, Hoad CL, Marciani L, Ban L, Prayle AP, et al. Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by magnetic resonance imaging. J Cyst Fibros. 2020.
36.
Dellon ES, Morgan DR, Mohanty SP, Davis K, Aris RM. High incidence of gastric bezoars in cystic fibrosis patients after lung transplantation. Transplantation. 2006;81(8):1141–6.PubMedCrossRef
37.
Hirji SA, Gulack BC, Englum BR, Speicher PJ, Ganapathi AM, Osho AA, et al. Lung transplantation delays gastric motility in patients without prior gastrointestinal surgery-a single-center experience of 412 consecutive patients. Clin Transplant. 2017;31(10).
38.
Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci. 2013;58(8):2275–81.PubMedCrossRef
39.
Malagelada C, Bendezu RA, Segui S, Vitria J, Merino X, Nieto A, et al. Motor dysfunction of the gut in cystic fibrosis. Neurogastroenterol Motil. 2020:e13883.
40.
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37 quiz 8.PubMedCrossRef
41.
Tonelli AR, Drane WE, Collins DP, Nichols W, Antony VB, Olson EL. Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. J Cyst Fibros. 2009;8(3):193–7.PubMedCrossRef
42.
El-Chammas KI, Rumman N, Goh VL, Quintero D, Goday PS. Rectal prolapse and cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60(1):110–2.PubMedCrossRef
43.
Stern RC, Izant RJ Jr, Boat TF, Wood RE, Matthews LW, Doershuk CF. Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology. 1982;82(4):707–10.PubMedCrossRef
44.
Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One. 2017;12(5):e0174463.PubMedPubMedCentralCrossRef
45.
van der Doef HP, Kokke FT, Beek FJ, Woestenenk JW, Froeling SP, Houwen RH. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. J Cyst Fibros. 2010;9(1):59–63.PubMedCrossRef
46.
Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40–S9.PubMedCrossRef
47.
Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009;137(3):976–85.PubMedCrossRef
48.
O'Brien CE, Anderson PJ, Stowe CD. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study. Ann Pharmacother. 2011;45(9):1061–6.PubMedCrossRef
49.
Arora K, Huang Y, Mun K, Yarlagadda S, Sundaram N, Kessler MM, et al. Guanylate cyclase 2C agonism corrects CFTR mutants. JCI Insight. 2017;2(19).
50.
Ahsan MK, Tchernychev B, Kessler MM, Solinga RM, Arthur D, Linde CI, et al. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine. Physiol Rep. 2017;5(11).
51.
McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, et al. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol. 2018;315(5):G868–G78.PubMedCrossRef
52.
Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354–60.PubMedCrossRef
53.
Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81.PubMedPubMedCentralCrossRef
54.
Houwen RH, van der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010;50(1):38–42.PubMedCrossRef
55.
Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10(Suppl 2):S24–8.PubMedCrossRef
56.
Green J, Gilchrist FJ, Carroll W. Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2018;6:CD012619.PubMed
57.
Abraham JM, Sabharwal S, Grand R, Mascarenhas M. Recommendations of the task force on distal intestinal obstruction syndrome. Bethesda, MD, USA: Cystic Fibrosis Foundation; 2016. [PortCF]
58.••
Neglia JP, FitzSimmons SC, Maisonneuve P, Schoni MH, Schoni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J med. 1995;332(8):494–9 Initial report of increased GI cancers in CF.PubMedCrossRef
59.••
Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):758–67 Large systematic review showing increased risk of GI cancers in CF.PubMedCrossRef
60.
Schoni MH, Maisonneuve P, Schoni-Affolter F, Lowenfels AB. Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group. J R Soc Med. 1996;89(Suppl 27):38–43.PubMedPubMedCentral
61.
Safaeian M, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF Jr, Engels EA. Risk of colorectal cancer after solid organ transplantation in the United States. Am J Transplant. 2016;16(3):960–7.PubMedPubMedCentralCrossRef
62.
Prenner S, Levitsky J. Comprehensive review on colorectal cancer and transplant. Am J Transplant. 2017;17(11):2761–74.PubMedCrossRef
63.
Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros. 2017;16(1):91–7.PubMedCrossRef
64.
Maiuri L, Raia V, Piacentini M, Tosco A, Villella VR, Kroemer G. Cystic fibrosis transmembrane conductance regulator (CFTR) and autophagy: hereditary defects in cystic fibrosis versus gluten-mediated inhibition in celiac disease. Oncotarget. 2019;10(43):4492–500.PubMedPubMedCentralCrossRef
65.
Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene. 2017;36(24):3504.PubMedCrossRef
66.
Scott P, Anderson K, Singhania M, Cormier R. Cystic fibrosis, CFTR, and colorectal cancer. Int J Mol Sci. 2020;21(8).
67.
68.
Strubberg AM, Liu J, Walker NM, Stefanski CD, MacLeod RJ, Magness ST, et al. Cftr modulates Wnt/beta-catenin signaling and stem cell proliferation in murine intestine. Cell Mol Gastroenterol Hepatol. 2018;5(3):253–71.PubMedCrossRef
69.•
Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol. 2014;48(9):e85–8 Initial report of increased colon polyps for individuals with CF at younger age.PubMedCrossRef
70.
Niccum DE, Billings JL, Dunitz JM, Khoruts A. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. J Cyst Fibros. 2016;15(4):548–53.PubMedPubMedCentralCrossRef
71.••
Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, et al. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154(3):736–45 e14 First colorectal cancer screening guidelines in CF.PubMedCrossRef
72.
Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, et al. Cost effectiveness of screening individuals with cystic fibrosis for colorectal cancer. Gastroenterology. 2018;154(3):556–67 e18.PubMedCrossRef
73.
Matson AG, Bunting JP, Kaul A, Smith DJ, Stonestreet J, Herd K, et al. A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. BMC Gastroenterol. 2019;19(1):89.PubMedPubMedCentralCrossRef
74.
Ramsay KA, Sandhu H, Geake JB, Ballard E, O'Rourke P, Wainwright CE, et al. The changing prevalence of pulmonary infection in adults with cystic fibrosis: a longitudinal analysis. J Cyst Fibros. 2017;16(1):70–7.PubMedCrossRef
75.
Hatziagorou E, Orenti A, Drevinek P, Kashirskaya N, Mei-Zahav M, De Boeck K, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry. J Cyst Fibros. 2020;19(3):376–83.PubMedCrossRef
76.
77.
Kristensen M, Prevaes S, Kalkman G, Tramper-Stranders GA, Hasrat R, de Winter-de Groot KM, et al. Development of the gut microbiota in early life: the impact of cystic fibrosis and antibiotic treatment. J Cyst Fibros. 2020;19(4):553–61.PubMedCrossRef
78.
Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, O'Sullivan O, et al. The altered gut microbiota in adults with cystic fibrosis. BMC Microbiol. 2017;17(1):58.PubMedPubMedCentralCrossRef
79.
Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007;44(2):212–8.PubMedCrossRef
80.
Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019;54(3):261–70.PubMedCrossRef
81.
Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–78.PubMedCrossRef
82.
Lisowska A, Pogorzelski A, Oracz G, Siuda K, Skorupa W, Rachel M, et al. Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth. J Cyst Fibros. 2011;10(6):418–21.PubMedCrossRef
83.
De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2007;293(3):G577–84.PubMedCrossRef
84.
Peach SL, Borriello SP, Gaya H, Barclay FE, Welch AR. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol. 1986;39(9):1013–8.PubMedPubMedCentralCrossRef
85.
Burke DG, Harrison MJ, Fleming C, McCarthy M, Shortt C, Sulaiman I, et al. Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J Cyst Fibros. 2017;16(2):291–8.PubMedCrossRef
86.
Bauer MP, Farid A, Bakker M, Hoek RA, Kuijper EJ, van Dissel JT. Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile. Clin Microbiol Infect. 2014;20(7):O446–9.PubMedCrossRef
87.
Monaghan TM, Negm OH, MacKenzie B, Hamed MR, Shone CC, Humphreys DP, et al. High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection. Clin Exp Gastroenterol. 2017;10:169–75.PubMedPubMedCentralCrossRef
88.
Egressy K, Jansen M, Meyer KC. Recurrent Clostridium difficile colitis in cystic fibrosis: an emerging problem. J Cyst Fibros. 2013;12(1):92–6.PubMedCrossRef
89.
McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.PubMedPubMedCentralCrossRef
90.
Dunwoody R, Steel A, Landy J, Simmonds N. Clostridium difficile and cystic fibrosis: management strategies and the role of faecal transplantation. Paediatr Respir Rev. 2018;26:16–8.PubMed
91.
Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, et al. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J. 2019;7(7):881–8.PubMedPubMedCentralCrossRef
92.
Lusman SS, Grand R. Approach to chronic abdominal pain in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S24–31.PubMedCrossRef
93.
Adams C, Icheva V, Deppisch C, Lauer J, Herrmann G, Graepler-Mainka U, et al. Long-term pulmonal therapy of cystic fibrosis-patients with amitriptyline. Cell Physiol Biochem. 2016;39(2):565–72.PubMedCrossRef
94.
Walkowiak J, Blask-Osipa A, Lisowska A, Oralewska B, Pogorzelski A, Cichy W, et al. Cystic fibrosis is a risk factor for celiac disease. Acta Biochim Pol. 2010;57(1):115–8.PubMedCrossRef
95.
Fluge G, Olesen HV, Gilljam M, Meyer P, Pressler T, Storrosten OT, et al. Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. J Cyst Fibros. 2009;8(3):198–202.PubMedCrossRef
96.
Holsclaw DS, Rocmans C, Shwachman H. Intussusception in patients with cystic fibrosis. Pediatrics. 1971;48(1):51–8.PubMed
97.
Nash EF, Stephenson A, Helm EJ, Ho T, Thippanna CM, Ali A, et al. Intussusception in adults with cystic fibrosis: a case series with review of the literature. Dig Dis Sci. 2011;56(12):3695–700.PubMedCrossRef
98.
Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet. 1994;343(8889):85–6.PubMedCrossRef
99.
Nakajima K, Oshida H, Muneyuki T, Kakei M. Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency. Core Evid. 2012;7:77–91.PubMedPubMedCentralCrossRef
100.
Smyth RL, Ashby D, O'Hea U, Burrows E, Lewis P, van Velzen D, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet. 1995;346(8985):1247–51.PubMedCrossRef
101.
Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S70–S8.PubMedCrossRef
Metadaten
Titel
Luminal Gastrointestinal Manifestations of Cystic Fibrosis
verfasst von
Samuel J Burton
Christine Hachem
James M. Abraham
Publikationsdatum
01.03.2021
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 3/2021
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-021-00806-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise